Steven Kelly - 28 Jan 2025 Form 4 Insider Report for Carisma Therapeutics Inc. (CARM)

Reporting relationship: President and CEO, Director
Issuer ticker: CARM
Reported as of: 28 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jan 2025, 16:01:15 UTC
Prior SEC filing: 23 Dec 2024
Next SEC filing: 02 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Steven Kelly

Key filing fact

Steven Kelly filed Form 4 for Carisma Therapeutics Inc. (CARM) on 30 Jan 2025.

Key facts

This page summarizes Steven Kelly's Form 4 filing for Carisma Therapeutics Inc. (CARM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jan 2025, 16:01.

Change

Previous filing in this sequence was filed on 23 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CARM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 28 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.5000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.